These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21953502)

  • 1. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.
    Azzopardi N; Lecomte T; Ternant D; Boisdron-Celle M; Piller F; Morel A; Gouilleux-Gruart V; Vignault-Desvignes C; Watier H; Gamelin E; Paintaud G
    Clin Cancer Res; 2011 Oct; 17(19):6329-37. PubMed ID: 21953502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
    Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
    Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer.
    Pointreau Y; Azzopardi N; Ternant D; Calais G; Paintaud G
    Ther Drug Monit; 2016 Oct; 38(5):567-72. PubMed ID: 27631463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
    Tabernero J; Van Cutsem E; Díaz-Rubio E; Cervantes A; Humblet Y; André T; Van Laethem JL; Soulié P; Casado E; Verslype C; Valera JS; Tortora G; Ciardiello F; Kisker O; de Gramont A
    J Clin Oncol; 2007 Nov; 25(33):5225-32. PubMed ID: 18024868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
    Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
    Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
    J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer.
    Climente-Martí M; Merino-Sanjuán M; Almenar-Cubells D; Jiménez-Torres NV
    J Pharm Sci; 2003 Jun; 92(6):1155-65. PubMed ID: 12761805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors.
    Tan AR; Moore DF; Hidalgo M; Doroshow JH; Poplin EA; Goodin S; Mauro D; Rubin EH
    Clin Cancer Res; 2006 Nov; 12(21):6517-22. PubMed ID: 17065274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.
    Dirks NL; Nolting A; Kovar A; Meibohm B
    J Clin Pharmacol; 2008 Mar; 48(3):267-78. PubMed ID: 18218786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters.
    Burz C; Berindan-Neagoe I; Balacescu O; Todor N; Pelau D; Floares C; Kacso G; Tanaselia C; Ursu M; Vlase L; Leucuta SE; Cristea V; Irimie A
    J BUON; 2010; 15(2):263-9. PubMed ID: 20658719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose and time dependencies of 5-fluorouracil pharmacokinetics.
    Terret C; Erdociain E; Guimbaud R; Boisdron-Celle M; McLeod HL; Féty-Deporte R; Lafont T; Gamelin E; Bugat R; Canal P; Chatelut E
    Clin Pharmacol Ther; 2000 Sep; 68(3):270-9. PubMed ID: 11014408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.
    Capitain O; Asevoaia A; Boisdron-Celle M; Poirier AL; Morel A; Gamelin E
    Clin Colorectal Cancer; 2012 Dec; 11(4):263-7. PubMed ID: 22683364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients.
    Lobet S; Paintaud G; Azzopardi N; Passot C; Caulet M; Chautard R; Desvignes C; Capitain O; Tougeron D; Lecomte T; Ternant D
    Clin Pharmacokinet; 2023 Sep; 62(9):1263-1274. PubMed ID: 37442917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative dosing schedules for cetuximab: a role for biweekly administration?
    Ramanathan RK
    Clin Colorectal Cancer; 2008 Nov; 7(6):364-8. PubMed ID: 19036688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.